A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice

CompletedOBSERVATIONAL
Enrollment

240

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

April 24, 2023

Study Completion Date

September 5, 2023

Conditions
Multiple MyelomaImmunoglobulin Light-chain Amyloidosis
Trial Locations (14)

1009

H. Universitario de Araba, Vitoria-Gasteiz

7120

H. Universitari Son Espases, Palma de Mallorca

9006

Hospital Universitario de Burgos, Burgos

11009

H. Puerta del Mar, Cadiz

15706

C.H.U. Santiago, Santiago de Compostela

24071

H. Universitario de Leon, León

27003

H. Universitario Lucus Agusti, Lugo

28040

H. Universitario Fundacion Jimenez Diaz, Madrid

29010

Hospital Regional Universitario de Malaga (Carlos de Haya), Málaga

30202

Hospital General Universitario Santa Lucia, Cartagena

33394

H. Universitario de Cabuenes, Gijón

37007

C.H. Salamanca, Salamanca

38320

C.H.U. Canarias, San Cristóbal de La Laguna

39008

H. Universitario Marques de Valdecilla, Santander

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Takeda

INDUSTRY

NCT04659798 - A Study to Investigate the Relationship Between Duration of Treatment and Response in Patients With Multiple Myeloma (MM) or Systemic AL Amyloidosis Treated in Real-life Practice | Biotech Hunter | Biotech Hunter